Fig. 1 · Structure

Documents & Downloads

CGP 3466B maleate

Cat. No. A12385 CAS 200189-97-5

GAPDH inhibitor

CGP 3466B maleate is an orally active glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

CGP 3466B maleate Research Summary

This section summarizes 4 in vivo studies of CGP 3466B maleate from 3 published references.

CGP 3466B maleate In Vivo Studies

In dyW/mag mice carrying the chick mini-agrin transgene, daily CGP 3466B treatment significantly lowered blood CK levels compared with vehicle-treated dyW/mag mice. Treatment also reduced muscle fibre loss in this model without completely normalizing fibre numbers. In the EAE mouse model, treatment prevented GAPDH nitrosylation in spinal cord lysates, with maximal effect at 4 mg/kg. In ethanol-pretreated mice receiving APAP, treatment produced no statistically significant difference in serum ALT compared with EtOH/APAP alone. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Blood CK reduction in dyW/mag mice

Animal study · dyW/mag mice; C57BL/6J mice; N ≥ 6 ≤ 8 [1]

In dyW/mag mice carrying the chick mini-agrin transgene, daily omigapil treatment at 0.1 mg/kg significantly lowered blood CK levels compared with vehicle-treated dyW/mag mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Blood CK levels expressed as percentage of control.Reported result dyW/mag mice treated daily with 0.1 mg/kg omigapil: Omigapil treatment in dyW/mag mice significantly lowers the CK levels (p = 0.023).[1]

Conditions shared by the study groups

Route
intraperitoneal injection; oral gavage
Treatment course
treatment started at the age of 15 days; For the first week of drug treatment; once daily; After weaning (3 weeks of age); Mice were analysed at the age of 12 weeks.
Vehicle
0.5% ethanol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CGP 3466B 0.1 mg/kgAge-matched animals treated with vehicle onlydyW/mag mice treated daily with 0.1 mg/kg omigapil: Omigapil treatment in dyW/mag mice significantly lowers the CK levels (p = 0.023).[1]
CGP 3466B 0.1 mg/kg
Model: dyW/mag mice; C57BL/6J mice; N ≥ 6 ≤ 8
Methods and source locations

Compound reported in the paper: CGP 3466B; Compound label in the paper: Omigapil

The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.

RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S84, S86, S87); MATERIALS AND METHODS > Mice (S96, S100); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106, S107); Figure 7 legend (S237, S238)

Blood CK levels expressed as percentage of control.: Blood CK levels expressed as percentage of control.; comparator: Age-matched animals treated with vehicle only — Figure 7 legend (S237, S238)

CGP 3466B 0.1 mg/kg · RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S86); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106); Figure 7 legend (S237, S238)

Prevention of GAPDH nitrosylation in EAE mice

Animal study · MOG35 − 55 EAE mouse model of MS; three mice per group [2]

In the EAE mouse model, daily intraperitoneal CGP3466b treatment prevented GAPDH nitrosylation in spinal cord lysates compared with vehicle, with maximal effect at 4 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GAPDH nitrosylation was measured by biotin switch assay from spinal cord lysates at PID 15Reported result CGP3466b treatment prevented GAPDH nitrosylation, with maximal effect at 4 mg/kg.[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
daily via intraperitoneal (i.p.) injection beginning on PID 0
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CGP 3466B 4 mg/kgvehicleCGP3466b treatment prevented GAPDH nitrosylation, with maximal effect at 4 mg/kg.[2]
CGP 3466B 4 mg/kg
Model: MOG35 − 55 EAE mouse model of MS; three mice per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: CGP 3466B

The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.

2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8); Figure 1 legend (S48, S57, S59)

GAPDH nitrosylation was measured by biotin switch assay from spinal cord lysates at PID 15: GAPDH nitrosylation was measured by biotin switch assay from spinal cord lysates at PID 15; comparator: vehicle — 2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8)

CGP 3466B 4 mg/kg · 2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8); Figure 1 legend (S57)

Serum ALT response in ethanol and APAP exposed mice

Animal study · female C57BL/6J mice; ethanol pre-treated mice; n = 8 [3]

In ethanol-pretreated female mice receiving APAP, intraperitoneal TCH346 treatment at 0.2 mg/kg or 1.0 mg/kg produced no statistically significant difference in serum ALT compared with EtOH/APAP alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum ALT levelsReported result 0.2 mg/kg TCH346; 1.0 mg/kg TCH346: There was no statistically significant difference in serum ALT between the EtOH/APAP groups receiving TCH346 as compared to EtOH/APAP alone.[3]

Conditions shared by the study groups

Route
intraperitoneal (IP) drug administration
Treatment course
fasted for 8 hours (h) before intraperitoneal (IP) drug administration, and sacrificed by CO2 inhalation after 4h
Vehicle
sterile PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CGP 3466B 0.2 mg/kg; 1.0 mg/kgEtOH/APAP alone0.2 mg/kg TCH346; 1.0 mg/kg TCH346: There was no statistically significant difference in serum ALT between the EtOH/APAP groups receiving TCH346 as compared to EtOH/APAP alone.[3]
CGP 3466B 0.2 mg/kg; 1.0 mg/kg
Model: female C57BL/6J mice; ethanol pre-treated mice; n = 8
Methods and source locations

Compound reported in the paper: CGP 3466B; Compound label in the paper: TCH-346

The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.

Materials and Methods > Liquid ethanol diet (S2, S3, S4); Materials and Methods > Drug treatments, blood and tissue processing (S6, S7, S8); Fig 3 legend (S70, S71)

Serum ALT levels: Serum ALT levels; comparator: EtOH/APAP alone — Materials and Methods > Drug treatments, blood and tissue processing (S6); Fig 3 legend (S70, S71)

CGP 3466B 0.2 mg/kg; 1.0 mg/kg · Materials and Methods > Drug treatments, blood and tissue processing (S6, S8); Fig 3 legend (S71)

Muscle fibre preservation in dyW/mag mice

Animal study · dyW/mag mice; C57BL/6J mice; N = 5 [1]

In dyW/mag mice carrying the chick mini-agrin transgene, daily omigapil treatment at 0.1 mg/kg reduced muscle fibre loss compared with vehicle-treated dyW/mag mice but did not completely normalize fibre numbers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total number of fibres per triceps cross-section.Reported result dyW/mag mice treated daily with 0.1 mg/kg omigapil: Omigapil treatment reduces muscle fibre loss in dyW/mag (p = 0.006) but does not completely normalize fibre numbers.[1]

Conditions shared by the study groups

Route
intraperitoneal injection; oral gavage
Treatment course
treatment started at the age of 15 days; For the first week of drug treatment; once daily; After weaning (3 weeks of age); Mice were analysed at the age of 12 weeks.
Vehicle
0.5% ethanol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CGP 3466B 0.1 mg/kgAge-matched animals treated with vehicle onlydyW/mag mice treated daily with 0.1 mg/kg omigapil: Omigapil treatment reduces muscle fibre loss in dyW/mag (p = 0.006) but does not completely normalize fibre numbers.[1]
CGP 3466B 0.1 mg/kg
Model: dyW/mag mice; C57BL/6J mice; N = 5
Methods and source locations

Compound reported in the paper: CGP 3466B; Compound label in the paper: Omigapil

The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.

RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S84, S86, S87); MATERIALS AND METHODS > Mice (S96, S100); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106, S107); Figure 7 legend (S237, S242, S243)

Total number of fibres per triceps cross-section.: Total number of fibres per triceps cross-section.; comparator: Age-matched animals treated with vehicle only — Figure 7 legend (S237, S242, S243)

CGP 3466B 0.1 mg/kg · RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S86); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106); Figure 7 legend (S237, S243)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 200189-97-5
Applications GAPDH inhibitor
Formula C19H17NO.C4H4O4
Molecular Weight 391.42
Synonyms TCH 346 maleate; CGP3466B; TCH346
SMILES
CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31.C(=C\C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

CGP 3466B maleate Research References

  1. [1] Meinen S, Lin S, Thurnherr R, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med (2011). PMID: 21674808 DOI: 10.1002/emmm.201100151 Source material
  2. [2] Godfrey WH, Hwang S, Cho K, et al. Therapeutic potential of blocking GAPDH nitrosylation with CGP3466b in experimental autoimmune encephalomyelitis. Front Neurol (2022). PMID: 36761918 DOI: 10.3389/fneur.2022.979659 Source material
  3. [3] Snider NT, Portney DA, Willcockson HH, et al. Ethanol and Acetaminophen Synergistically Induce Hepatic Aggregation and TCH346-Insensitive Nuclear Translocation of GAPDH. PLoS One (2016). PMID: 27513663 DOI: 10.1371/journal.pone.0160982 Source material

Added to your cart

View Cart Checkout
Loading...